The 26RFa (QRFP)/GPR103 neuropeptidergic system: A key regulator of energy and glucose metabolism

M Devère, S Takhlidjt, G Prévost, N Chartrel… - …, 2024 - karger.com
Background: Obesity and type 2 diabetes are strongly associated pathologies, currently
considered as a worldwide epidemic problem. Understanding the mechanisms that drive the …

Why Search for Alternative GPCR Agonists?

JA Boutin, J Leprince - Receptors, 2023 - mdpi.com
Intuitively, it is easy to understand why we search for G protein-coupled receptor (GPCR)
antagonists. It is obviously to block a functionality of a specific receptor potentially linked to …

[Retracted] Identification of Key Genes Related to the Obesity Patients with Osteoarthritis Based on Weighted Gene Coexpression Network Analysis (WGCNA)

Q Zhou, H Sun, J Jia, J Jiang, T Li… - … Methods in Medicine, 2022 - Wiley Online Library
Background. Increasing evidence has suggested that obesity affects the occurrence and
progression of osteoarthritis (OA). However, the underlying molecular mechanism that …

Point-Substitution of Phenylalanine Residues of 26RFa Neuropeptide: A Structure-Activity Relationship Study

B Lefranc, K Alim, C Neveu, O Le Marec, C Dubessy… - Molecules, 2021 - mdpi.com
26RFa is a neuropeptide that activates the rhodopsin-like G protein-coupled receptor
QRFPR/GPR103. This peptidergic system is involved in the regulation of a wide array of …

An alkyne-functionalized arginine for solid-phase synthesis enabling “bioorthogonal” peptide conjugation

K Spinnler, L von Krüchten, A Konieczny… - ACS Medicinal …, 2019 - ACS Publications
Lately, amino-functionalized N ω-carbamoylated arginines were introduced as arginine
surrogates enabling peptide labeling. However, this approach is hardly compatible with …

The 26RFa (QRFP)/GPR103 Neuropeptidergic System: A Key Regulator of Energy and Glucose Metabolism

MDSTG Prévosta, N Chartrela, J Leprincea, M Picota - 2024 - karger.com
Background: Obesity and type 2 diabetes are strongly associated pathologies, currently
considered as a worldwide epidemic problem. Understanding the mechanisms that drive the …

Platelet-activating factor receptor in GtoPdb v. 2023.1

R Hills, S Ishii, S Jancar, T McIntyre… - IUPHAR/BPS Guide …, 2023 - journals.ed.ac.uk
Abstract Platelet-activating factor (PAF, 1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine) is
an ether phospholipid mediator associated with platelet coagulation, but also subserves …

Design, synthesis novel Pyrazolopyridine derivatives and CREBBP bromodomain inhibitors docking and molecular dynamics

M Saamanthi, S Aruna, R Girija, D Vinod - Materials Today: Proceedings, 2021 - Elsevier
The overall synthetic approach was used to prepare a series of novel compounds
pyrazolopyridine. Because of its high efficiency and selectiveness, the combined molecules …